RxDoctor Payments Data

Blessing Jerome, MD

Internal Medicine · Las Vegas, NVNPI 1235791377

Payments from drug & device makers

$414in general payments, 2019–2025

Across 23 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$136
  • AstraZeneca$79
  • GSK$63
  • Pfizer$49
  • Exact Sciences$44
  • Lilly USA, LLC$29
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$414100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$414 in reported general payments places this provider in the 55th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$5,305
Medicare patients
29
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin178$220,753
OzempicSemaglutide89$161,666
EliquisApixaban78$91,941
RybelsusSemaglutide22$62,435
TrulicityDulaglutide34$54,942
FarxigaDapagliflozin Propanediol45$51,992
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$48,834
JanuviaSitagliptin Phosphate19$34,693
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$32,629
MounjaroTirzepatide19$32,388
DapagliflozinDapagliflozin Propanediol13$13,886
Breo ElliptaFluticasone/Vilanterol23$11,260
XareltoRivaroxaban11$10,377
Tresiba Flextouch U-100Insulin Degludec13$10,351
Lantus SolostarInsulin Glargine,hum.Rec.Anlog72$8,776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$136$224,101111 claims
Boehringer IngelheimJardiance$15$220,753178 claims
PfizerEliquis$49$91,94178 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$79$87,56186 claims
Lilly USA, LLCTrulicity, Mounjaro$29$87,33053 claims
GSKTrelegy Ellipta, Breo Ellipta$63$60,09371 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →